Keloid Research welcomes submission of all manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is ‘any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome’. Keloid Research follows the trial registration policy of the ICMJE and considers only trials that have been registered before submission, and before the onset of patient enrollment.
For authors reporting phase II and phase III randomized controlled trials it is recommended to consult the CONSORT Statement and Checklist to facilitate the complete and transparent reporting of trial findings. In addition, including a Patient Flow Diagram in the manuscript is recommended for randomized studies. Authors must report the registration number and name of the trial registry at the end of the article abstract.
In accordance with the guidelines published by the International Committee of Medical Journal Editors (ICMJE), Keloid Research requires that all clinical trials be registered in any of the primary registers that participate in the WHO International Clinical Trial Registry Platform (ICTRP) or in EudraCT.
For more information, see the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
To ensure that NIH-funded manuscripts are correctly identified during submission, we request that authors use full titles and/or full acronyms when referring to NIH funding. Please also note that the corresponding author is responsible for disclosing NIH funding for all coauthors.